CXCR4 and Miyoshi myopathy: Ulocuplumab, a monoclonal anti-CXCR4 antibody, suppressed MM cell dissemination, suggesting the inhibition of EMT-like phenotype conversion of MM cells by targeting CXCR4 [100].